Comparative pharmacology of bipolar disorder and schizophrenia

Schizophrenia Research

Volumn 39, Issue 2, 1999, Pages 153-158

  Post, Robert M ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Bipolar disorder; Comparative pharmacology; Schizophrenia

Indexed keywords

ANTICONVULSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; OMEGA 3 FATTY ACID; TAMOXIFEN; TOPIRAMATE; VALPROIC ACID; VERAPAMIL;

BRAIN BLOOD FLOW; CONFERENCE PAPER; ELECTROCONVULSIVE THERAPY; HUMAN; MANIA; MANIC DEPRESSIVE PSYCHOSIS; PRIORITY JOURNAL; SCHIZOPHRENIA; TRANSCRANIAL MAGNETIC STIMULATION;

ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BRAIN; ELECTRIC STIMULATION THERAPY; HUMANS; MAGNETICS; SCHIZOPHRENIA;

EID: 0032835502     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(99)00115-2     Document Type: Conference Paper

References (48)

1. Ahlfors U.G., Baastrup P.C., Dencker S.J., Elgen K., Lingjaerde O., Pedersen V., Schou M., Aaskoven O. Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium. Acta Psychiatr. Scand. 64:1981;226-237.
2. Barkin J.S., Pais V.M. Jr., Gaffney M.F. Induction of mania by risperidone resistant to mood stabilizers. letter J. Clin. Psychopharmacol. 17:1997;57-58.
3. Bebchuk J.M., Arfken C.L., Dolan-Manji S., Murphy J.M., Manji H.K. A preliminary investigation of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania. abstract Arch. Gen. Psychiatry. 1999;. in press.
4. Bowden C.L. Predictors of response to divalproex and lithium. J. Clin. Psychiatry. 3:1995;25-30.
5. Brunet G., Cerlich B., Robert P., Dumas S., Souetre E., Darcourt G. Open trial of a calcium antagonist, nimodipine, in acute mania. Clin. Neuropharmacol. 13:1990;224-228.
6. Chen G., Zeng W.Z., Yuan P.X., Huang L.D., Jiang Y.M., Zhao Z.H., Manji H.K. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J. Neurochem. 72:1999;879-882.
7. Chen R.W., Chuang D.M. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J. Biol. Chem. 274:1999;6039-6042.
8. Coyle J.T. The glutamatergic dysfunction hypothesis for schizophrenia. Harv. Rev. Psychiatry. 3:1996;241-253.
9. Diaz S.F. Mania associated with risperidone use. letter J. Clin. Psychiatry. 57:1996;41-42.
10. Fink M. Convulsive Therapy: Theory and Practice. 1979;Raven Press, New York.
11. Frye M.A., Ketter T.A., Altshuler L.L., Denicoff K., Dunn R.T., Kimbrell T.A., Cora-Locatelli G., Post R.M. Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics. J. Affect. Disord. 48:1998;91-104.
12. George M.S., Wassermann E.M., Kimbrell T.A., Little J.T., Williams W.E., Danielson A.L., Greenberg B.D., Hallett M., Post R.M. Mood improvement following daily left prefrontal repetitive transcranial magnetic stimulation in patients with depression: a placebo-controlled crossover trial. Am. J. Psychiatry. 154:1997;1752-1756.
13. George M.S., Wassermann E.M., Williams W.A., Callahan A., Ketter T.A., Basser P., Hallett M., Post R.M. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. NeuroReport. 6:1995;1853-1856.
14. Greil W., Ludwig-Mayerhofer W., Erazo N., Engel R.R., Czernik A., Giedke H., Muller-Oerlinghausen B., Osterheider M., Rudolf G.A., Sauer H., Tegeler J., Wetterling T. Lithium vs carbamazepine in the maintenance treatment of schizoaffective disorder: a randomised study. Eur. Arch. Psychiatry Clin. Neurosci. 247:1997;42-50.
15. Grisaru N., Chudakov B., Yaroslavsky Y., Belmaker R.H. Transcranial magnetic stimulation in mania: a controlled study. Am. J. Psychiatry. 155:1998;1608-1610.
16. Hirschowitz J., Casper R., Garver D.L., Chang S. Lithium response in good prognosis schizophrenia. Am. J. Psychiatry. 137:1980;916-920.
17. Hough C.J., Irwin R.P., Gao X.-M., Rogawski M.A., Chuang D.M. Carbamazepine inhibition of N-methyl-D-aspartate-evoked calcium influx in rat cerebellar granule cells. J. Pharmacol. Exp. Ther. 276:1996;143-149.
18. Kane J.M., Woerner M., Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J. Clin. Psychopharmacol. 8:1988;52S-56S.
19. Koek R.J., Kessler C.C. Probable induction of mania by risperidone. letter J. Clin. Psychiatry. 57:1996;174-175.
20. Kukopulos A., Reginaldi D., Laddomada P., Floris G., Serra G., Tondo L. Course of the manic-depressive cycle and changes caused by treatment. Pharmakopsychiatr. Neuropsychopharmakol. 13:1980;156-167.
21. Leach J.P., Brodie M.J. Tiagabine. Lancet. 351:1998;203-207.
22. London. Mania associated with olanzapine. letter J. Am. Acad. Child Adolesc. Psychiatry. 37:1998;135-136.
23. Macdonald R.L., Kelly K.M. Antiepileptic drug mechanisms of action. Epilepsia. 36:(Suppl 2):1995;S2-S12.
24. McElroy S.L., Keck P.E. Jr., Pope H.G. Jr., Hudson J.I. Valproate in psychiatric disorders: literature review and clinical guidelines. J. Clin. Psychiatry. 50:1989;23-29.
25. Manji H.K., Bebchuk J.M., Moore G.J., Glitz D., Hasanat K.A., Chen G. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. J. Clin. Psychiatry. 60:(Suppl. 2):1999;27-39.
26. Margolis R.L., Chuang D.M., Post R.M. Programmed cell death: implications for neuropsychiatric disorders. Biol. Psychiatry. 35:1994;946-956.
27. Nasrallah H.A., Churchill C.M., Hamden-Allan G.A. Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia. Am. J. Psychiatry. 145:1988;1455-1456.
28. Nonaka S., Chuang D.M. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. NeuroReport. 9:1998;2081-2084.
29. Okuma T., Yamashita I., Takahashi R., Itoh H., Kurihara M., Otsuki S., Watanabe S., Sarai K., Hazama H., Inanaga K. Clinical efficacy of carbamazepine in affective, schizoaffective, and schizophrenic disorders. Pharmacopsychiatry. 22:1989;47-53.
30. Pascual-Leone A., Rubio B., Pallardo F., Catala M.D. Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet. 348:1996;233-237.
31. Pazzaglia P.J., Post R.M., Ketter T.A., Callahan A.M., Marangell L.B., Frye M.A., George M.S., Kimbrell T.A., Leverich G.S., Cora-Locatelli G., Luckenbaugh D. Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. J. Clin. Psychopharmacol. 18:1998;404-413.
32. Pazzaglia P.J., Post R.M., Ketter T.A., George M.S., Marangell L.B. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Res. 49:1993;257-272.
33. Pearlson G.D., Wong D.F., Tune L.E., Ross C.A., Chase G.A., Links J.M., Dannals R.F., Wilson A.A., Ravert H.T., Wagner H.N. Jr. In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder. Arch. Gen. Psychiatry. 52:1995;471-477.
34. Pickar D., Wolkowitz O.M., Doran A.R., Labarca R., Roy A., Breier A., Narang P.K. Clinical and biochemical effects of verapamil administration to schizophrenic patients. Arch. Gen. Psychiatry. 44:1987;113-118.
35. Post, R.M. Psychopharmacology of mood stabilizers. In: Buckley, P.F., Waddington, J.L. (Eds.), Schizophrenia and Mood Disorders: The New Drug Therapies in Clinical Practice. Butterworth-Heinemann, Oxford, in press.
36. Post R.M., Denicoff K.D., Frye M.A., Dunn R.T., Leverich G.S., Osuch E., Speer A. A history of the use of anticonvulsants as mood stabilizers in the last two decades of the 20th century. Neuropsychobiology. 38:1998;152-166.
37. Post R.M., Weiss S.R.B., Chuang D.M., Ketter T.A. Mechanisms of action of carbamazepine in seizure and affective disorders. Joffe R.T., Calabrese J.R. Anticonvulsants in Mood Disorders. 1994;43-92 Marcel Dekker, New York.
38. Reeves R.R., McBride W.A., Brannon G.E. Olanzapine-induced mania. J. Am. Osteopath. Assoc. 98:1998;549-550.
39. Schnierow B.J., Graeber D.A. Manic symptoms associated with initiation of risperidone. letter Am. J. Psychiatry. 153:1996;1235-1236.
40. Sedvall G., Farde L., Hall H., Halldin C., Karlsson P., Nordstrom A.L., Nyberg S., Pauli S. Utilization of radioligands in schizophrenia research. Clin. Neurosci. 3:1995;112-121.
41. Speer A.M., Kimbrell T.A., Dunn R.T., Osuch E.A., Frye M.A., Willis M.W., Wassermann E.M. Differential changes in rCBF with one versus 20 Hz rTMS in depressed patients. abstract APA New Res. Progr. Abstr. R55:1998;82.
42. Speer A.M., Kimbrell T.A., Wassermann E.M., Willis M.W., Post R.M. Differential effects of 1 Hz versus 20 Hz rTMS on mood and regional cerebral blood flow (rCBF): inplications for treatment of bipolar illness. abstract Bipolar Disorders. 1:(Suppl. 1):1999;52.
43. Stoll A.L., Severus W.E., Freeman M.P., Rueter S., Zboyan H.A., Diamond E., Cress K.K., Marangell L.B. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind placebo-controlled trial. Arch. Gen. Psychiatry. 56:1999;407-412.
44. Tamminga C.A., Crayton J.W., Chase T.N. Muscimol: GABA agonist therapy in schizophrenia. Am. J. Psychiatry. 135:1978;746-747.
45. 11C-N-methylspiperone. Psychiatry Res. 49:1993;219-237.
46. Woerner M.G., Alvir J.M., Saltz B.L., Lieberman J.A., Kane J.M. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am. J. Psychiatry. 155:1998;1521-1528.
47. Wolf M.E., De Wolfe A.S., Mosnaim A.D. Risk factors for tardive dyskinesia according to primary psychiatric diagnosis. Hillside J. Clin. Psychiatry. 9:1987;3-11.
48. Yassa R., Ghadirian A.M., Schwartz G. Prevalence of tardive dyskinesia in affective disorder patients. J. Clin. Psychiatry. 44:1983;410-412.